<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37981717</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-6256</ISSN><JournalIssue CitedMedium="Internet"><Volume>193</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of epidemiology</Title><ISOAbbreviation>Am J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.</ArticleTitle><Pagination><StartPage>1106</StartPage><EndPage>1114</EndPage><MedlinePgn>1106-1114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/aje/kwad225</ELocationID><Abstract><AbstractText>Postacute symptoms are not uncommon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with pre-Omicron variants. How the Omicron variant and coronavirus disease 2019 (COVID-19) booster vaccination influence the risk of postacute symptoms is less clear. We analyzed data from a nationwide Danish questionnaire study, EFTER-COVID, comprising 36 109 individuals aged &#x2265;15 years who were tested between July 2021 and January 2022, to evaluate the associations of the Omicron variant and COVID-19 booster vaccination with postacute symptoms and new-onset general health problems 4 months after infection with SARS-CoV-2. Risk differences (RDs) were estimated by comparing Omicron cases with controls, comparing Omicron cases with Delta cases, and comparing Omicron cases vaccinated with 3 doses with those vaccinated with 2 doses, adjusting for age, sex, body mass index, self-reported chronic diseases, Charlson comorbidity index, health-care occupation, and vaccination status. Four months after testing for SARS-CoV-2 during the Omicron period, cases experienced substantial postacute symptoms and new-onset health problems in comparison with controls; the largest RD was observed for memory issues (RD&#xa0;=&#xa0;7.4%; 95% CI, 6.4-8.3). However, risks were generally lower than those in the Delta period, particularly for dysosmia (RD&#xa0;=&#xa0;-15.0%; 95% CI, -17.0 to -13.2) and dysgeusia (RD&#xa0;=&#xa0;-11.2%; 95% CI, -13.2 to -9.5). Booster vaccination was associated with fewer postacute symptoms and new-onset health problems 4 months after Omicron infection as compared with 2 doses of COVID-19 vaccine.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spiliopoulos</LastName><ForeName>Lampros</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9668-3587</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Anna Irene Vedel</ForeName><Initials>AIV</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bager</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Nete Munk</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Focused Research Unit in Neurology, Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, 6200 Aabenraa, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>J&#xf8;rgen Vinsl&#xf8;v</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Rigshospitalet University Hospital, 2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health Section, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, 1014 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meder</LastName><ForeName>Inger Kristine</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Videbech</LastName><ForeName>Poul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Neuropsychiatric Depression Research, Mental Health Centre Glostrup, 2600 Glostrup, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ethelberg</LastName><ForeName>Steen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health Section, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, 1014 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hviid</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacovigilance Research Centre, Department of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Danish Ministry of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Epidemiol</MedlineTA><NlmUniqueID>7910653</NlmUniqueID><ISSNLinking>0002-9262</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Epidemiol. 2024 Jul 8;193(7):1059-1060. doi: 10.1093/aje/kwae021</RefSource><PMID Version="1">38497541</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Epidemiol. 2024 Aug 5;193(8):1203. doi: 10.1093/aje/kwae069</RefSource><PMID Version="1">38963409</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Omicron variant</Keyword><Keyword MajorTopicYN="N">booster vaccination</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute symptomatology</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList><CoiStatement>The authors received no support from any organization for this work. N.M.N. reports receiving grants from the A.P. M&#xf8;ller Foundation, Lilly and Herbert Hansen&#x2019;s Fund, and the Greenland Research Council, all unrelated to the present study. A.K. is the President of the Danish Greenlandic Society for Circumpolar Health and the Past President of the International Union for Circumpolar Health, unrelated to this study. A.H. is a Scientific Board Member of the Vaccine Monitoring Collaboration for Europe (VAC4EU) and reports receiving grants from the Novo Nordisk Foundation, the Danish Medical Research Council, the European Medicines Agency, the Lundbeck Foundation, and the Global Vaccine Data Network, all unrelated to the present study. The authors report no other relationships or activities that could appear to have influenced this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>5</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37981717</ArticleId><ArticleId IdType="pmc">PMC11299024</ArticleId><ArticleId IdType="doi">10.1093/aje/kwad225</ArticleId><ArticleId IdType="pii">7425620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Published October 6, 2021. Accessed October 4, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>S&#xf8;rensen &#xa0;AIV, Spiliopoulos &#xa0;L, Bager &#xa0;P, et&#xa0;al. &#xa0;A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat Commun. &#xa0;2022;13(1):4213&#x2013;4218. 10.1038/s41467-022-31897-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31897-x</ArticleId><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli &#xa0;M, Pujol &#xa0;JC, Spector &#xa0;TD, et&#xa0;al. &#xa0;Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. &#xa0;2022;399(10343):2263&#x2013;2264. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson &#xa0;K, Kristoffersen &#xa0;DT, Dell&#x2019;Isola &#xa0;A, et&#xa0;al. &#xa0;Post-covid medical complaints after SARS-CoV-2 Omicron vs Delta variants&#x2014;a prospective cohort study. medRxiv. &#xa0;10.1101/2022.05.23.22275445, May 25, 2022, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.23.22275445</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren &#xa0;O, Stehlik &#xa0;P, Clark &#xa0;J, et&#xa0;al. &#xa0;Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis. medRxiv. &#xa0;10.1101/2022.06.20.22276621, June 22, 2022, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.20.22276621</ArticleId></ArticleIdList></Reference><Reference><Citation>
Statens Serum Institut . EFTER-COVID [in Danish]. Updated December 11, 2023. Accessed August 29, 2022. https://covid19.ssi.dk/overvagningsdata/undersoegelser/efter-covid</Citation></Reference><Reference><Citation>Sch&#xf8;nning &#xa0;K, Dessau &#xa0;RB, Jensen &#xa0;TG, et&#xa0;al. &#xa0;Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark. APMIS. &#xa0;2021;129(7):438&#x2013;451. 10.1111/apm.13140</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.13140</ArticleId><ArticleId IdType="pmc">PMC8239934</ArticleId><ArticleId IdType="pubmed">33949007</ArticleId></ArticleIdList></Reference><Reference><Citation>Michlmayr &#xa0;D, Hansen &#xa0;CH, Gubbels &#xa0;SM, et&#xa0;al. &#xa0;Observed protection against SARS-CoV-2 reinfection following a primary infection: a Danish cohort study using two years of nationwide PCR-test data. &#xa0;SSRN. &#xa0;10.2139/ssrn.4054807, March 10, 2022, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4054807</ArticleId><ArticleId IdType="pmc">PMC9245510</ArticleId><ArticleId IdType="pubmed">35791335</ArticleId></ArticleIdList></Reference><Reference><Citation>Drent &#xa0;M, Lower &#xa0;EE, De Vries &#xa0;J. Sarcoidosis-associated fatigue. Eur Respir J. &#xa0;2012;40(1):255&#x2013;263. 10.1183/09031936.00002512</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00002512</ArticleId><ArticleId IdType="pubmed">22441750</ArticleId></ArticleIdList></Reference><Reference><Citation>De Kleijn &#xa0;WPE, De Vries &#xa0;J, Wijnen &#xa0;PAHM, et&#xa0;al. &#xa0;Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. &#xa0;2011;105(9):1388&#x2013;1395. 10.1016/j.rmed.2011.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2011.05.004</ArticleId><ArticleId IdType="pubmed">21700440</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries &#xa0;J, Michielsen &#xa0;H, Van Heck &#xa0;GL, et&#xa0;al. &#xa0;Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. &#xa0;2004;9(3):279&#x2013;291. 10.1348/1359107041557048</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/1359107041557048</ArticleId><ArticleId IdType="pubmed">15296678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotler &#xa0;J, Holtzman &#xa0;C, Dudun &#xa0;C, et&#xa0;al. &#xa0;A brief questionnaire to assess post-exertional malaise. Diagnostics. &#xa0;2018;8(3):66. 10.3390/diagnostics8030066</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics8030066</ArticleId><ArticleId IdType="pmc">PMC6165517</ArticleId><ArticleId IdType="pubmed">30208578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen &#xa0;JH, St&#xf8;ttrup &#xa0;MM, Nayberg &#xa0;E, et&#xa0;al. &#xa0;Optimising screening for cognitive dysfunction in bipolar disorder: validation and evaluation of objective and subjective tools. J Affect Disord. &#xa0;2015;187:10&#x2013;19. 10.1016/j.jad.2015.07.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2015.07.039</ArticleId><ArticleId IdType="pubmed">26301477</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa &#xa0;AR, Mercad&#xe9; &#xa0;C, S&#xe1;nchez-Moreno &#xa0;J, et&#xa0;al. &#xa0;Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J Affect Disord. &#xa0;2013;150:29&#x2013;36. 10.1016/j.jad.2013.02.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2013.02.022</ArticleId><ArticleId IdType="pubmed">23497792</ArticleId></ArticleIdList></Reference><Reference><Citation>

Pedersen &#xa0;CB, G&#xf8;tzsche &#xa0;H, M&#xf8;ller &#xa0;J&#xd8;, et&#xa0;al. &#xa0;The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. &#xa0;2006;53(4):441&#x2013;449. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2018-10/dmb3816.pdf
</Citation><ArticleIdList><ArticleId IdType="pubmed">17150149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynge &#xa0;E, Sandegaard &#xa0;JL, Rebolj &#xa0;M. The Danish National Patient Register. Scand J Public Health. &#xa0;2011;39(7):30&#x2013;33. 10.1177/1403494811401482</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1403494811401482</ArticleId><ArticleId IdType="pubmed">21775347</ArticleId></ArticleIdList></Reference><Reference><Citation>
Danish Patient Safety Authority . Autorisationsregistret [in Danish]. Accessed October 23, 2023. https://stps.dk/sundhedsfaglig/autorisation/autorisationsregistret</Citation></Reference><Reference><Citation>
Statistics Denmark. Dansk Branchekode DB07, v3:2014- [in Danish]. Accessed October 4, 2022. https://www.dst.dk/da/Statistik/dokumentation/nomenklaturer/db07</Citation></Reference><Reference><Citation>Quan &#xa0;H, Sundararajan &#xa0;V, Halfon &#xa0;P, et&#xa0;al. &#xa0;Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. &#xa0;2005;43(11):1130&#x2013;1139. 10.1097/01.mlr.0000182534.19832.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlr.0000182534.19832.83</ArticleId><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove Krause &#xa0;T, Jakobsen &#xa0;S, Haarh &#xa0;M, et&#xa0;al. &#xa0;The Danish Vaccination Register. Euro Surveill. &#xa0;2012;17(17):2. 10.2807/ese.17.17.20155-en</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/ese.17.17.20155-en</ArticleId><ArticleId IdType="pubmed">22551494</ArticleId></ArticleIdList></Reference><Reference><Citation>
Statens Serum Institut . Covid-19 Vaccine Dashboard (regional). [in Danish]. 2022. Accessed October 4, 2022. https://experience.arcgis.com/experience/9824b03b114244348ef0b10f69f490b4</Citation></Reference><Reference><Citation>Snowden &#xa0;JM, Rose &#xa0;S, Mortimer &#xa0;KM. Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol. &#xa0;2011;173(7):731&#x2013;738. 10.1093/aje/kwq472</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq472</ArticleId><ArticleId IdType="pmc">PMC3105284</ArticleId><ArticleId IdType="pubmed">21415029</ArticleId></ArticleIdList></Reference><Reference><Citation>Westreich &#xa0;D, Cole &#xa0;SR, Young &#xa0;JG, et&#xa0;al. &#xa0;The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med. &#xa0;2012;31(18):2000&#x2013;2009. 10.1002/sim.5316</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5316</ArticleId><ArticleId IdType="pmc">PMC3641816</ArticleId><ArticleId IdType="pubmed">22495733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahern &#xa0;J, Hubbard &#xa0;A, Galea &#xa0;S. Estimating the effects of potential public health interventions on population disease burden: a step-by-step illustration of causal inference methods. Am J Epidemiol. &#xa0;2009;169(9):1140&#x2013;1147. 10.1093/aje/kwp015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp015</ArticleId><ArticleId IdType="pmc">PMC2732980</ArticleId><ArticleId IdType="pubmed">19270051</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins &#xa0;J. A new approach to causal inference in mortality studies with a sustained exposure period&#x2014;application to control of the healthy worker survivor effect. Math Model. &#xa0;1986;7(9-12):1393&#x2013;1512. 10.1016/0270-0255(86)90088-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0270-0255(86)90088-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole &#xa0;TJ, Bellizzi &#xa0;MC, Flegal &#xa0;KM, et&#xa0;al. &#xa0;Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J. &#xa0;2000;320(7244):1240&#x2013;1243. 10.1136/bmj.320.7244.1240</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.320.7244.1240</ArticleId><ArticleId IdType="pmc">PMC27365</ArticleId><ArticleId IdType="pubmed">10797032</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team . R: A Language and Environment for Statistical Computing.
R Foundation for Statistical Computing; 2022. Accessed October 4, 2022. http://www.R-project.org/</Citation></Reference><Reference><Citation>Grembi &#xa0;JA, Rogawski McQuade &#xa0;ET. Introducing riskCommunicator: an R package to obtain interpretable effect estimates for public health. PloS One. &#xa0;2022;17(7):e0265368. 10.1371/journal.pone.0265368</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0265368</ArticleId><ArticleId IdType="pmc">PMC9292119</ArticleId><ArticleId IdType="pubmed">35849588</ArticleId></ArticleIdList></Reference><Reference><Citation>

Dayimu &#xa0;A. &#xa0;forestploter: Create Flexible Forest Plot. Version 1.1.1. Published March 21, 2022. Accessed January 4, 2024. https://cran.rstudio.com/web/packages/forestploter/index.html</Citation></Reference><Reference><Citation>Yoo &#xa0;SM, Liu &#xa0;TC, Motwani &#xa0;Y, et&#xa0;al. &#xa0;Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med. &#xa0;2022;37(8):1988&#x2013;1995. 10.1007/s11606-022-07523-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07523-3</ArticleId><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; &#xa0;A, Bernabei &#xa0;R, Landi &#xa0;F, et&#xa0;al. &#xa0;Persistent symptoms in patients after acute COVID-19. JAMA. &#xa0;2020;324(6):603&#x2013;605. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund &#xa0;LC, Hallas &#xa0;J, Nielsen &#xa0;H, et&#xa0;al. &#xa0;Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. &#xa0;2021;21(10):1373&#x2013;1382. 10.1016/S1473-3099(21)00211-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 7 July 2022. Published July 7, 2022. Accessed July 7, 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongo-ingsymptomsfollowingcoronaviruscovid19infectionintheuk/7july2022</Citation></Reference><Reference><Citation>Xie &#xa0;Y, Bowe &#xa0;B, Al-Aly &#xa0;Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. &#xa0;2021;12(1):6571&#x2013;6512. 10.1038/s41467-021-26513-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26513-3</ArticleId><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly &#xa0;Z, Bowe &#xa0;B, Xie &#xa0;Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. &#xa0;2022;28(7):1461&#x2013;1467. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>
Danish Broadcasting Corporation . Klinniker oplever markant fald i antallet af patienter, der bliver henvist med coronasenf&#xf8;lger [in Danish]. Published June 26, 2022. Accessed October 4, 2022. https://www.dr.dk/nyheder/indland/klinikker-oplever-markant-fald-i-antallet-af-patienter-der-bliver-henvist-med</Citation></Reference><Reference><Citation>Antonelli &#xa0;M, Penfold &#xa0;RS, Merino &#xa0;J, et&#xa0;al. &#xa0;Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. &#xa0;2022;22(1):43&#x2013;55. 10.1016/S1473-3099(21)00460-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>